395 related articles for article (PubMed ID: 30397793)
1. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
Sukgen EA; Koçluk Y
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.
Cheng Y; Zhu X; Linghu D; Liang J
Acta Ophthalmol; 2020 Dec; 98(8):e1004-e1008. PubMed ID: 32385940
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity.
Vedantham V
Indian J Ophthalmol; 2019 Jun; 67(6):884-888. PubMed ID: 31124509
[TBL] [Abstract][Full Text] [Related]
4. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
[TBL] [Abstract][Full Text] [Related]
5. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
6. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C
Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
Ekinci DY; Çelik K
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
[TBL] [Abstract][Full Text] [Related]
8. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.
Süren E; Özkaya D; Çetinkaya E; Kalaycı M; Yiğit K; Kücük MF; Erol MK
Int Ophthalmol; 2022 Jun; 42(6):1905-1913. PubMed ID: 35094229
[TBL] [Abstract][Full Text] [Related]
9. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
11. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.
Ortiz-Seller A; Martorell P; Barranco H; Pascual-Camps I; Morcillo E; Ortiz JL
Surv Ophthalmol; 2024; 69(4):585-605. PubMed ID: 38432359
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
Tong Q; Yin H; Zhao M; Li X; Yu W
BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Aflibercept Treatment and Its Effect on the Retinal Perfusion in the Oxygen-Induced Retinopathy Mouse Model of Retinopathy of Prematurity.
Amin SM; Gonzalez A; Guevara J; Bolch C; Andersen L; Smith WC; Agarwal-Sinha S
Ophthalmic Res; 2021; 64(1):91-98. PubMed ID: 32535604
[TBL] [Abstract][Full Text] [Related]
15. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
Stahl A; Sukgen EA; Wu WC; Lepore D; Nakanishi H; Mazela J; Moshfeghi DM; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Schmelter T; Leal S; Köfüncü E; Azuma N;
JAMA; 2022 Jul; 328(4):348-359. PubMed ID: 35881122
[TBL] [Abstract][Full Text] [Related]
16. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
18. INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION.
Cho HJ; Hwang HJ; Kim HS; Han JI; Lee DW; Kim JW
Retina; 2018 Nov; 38(11):2150-2158. PubMed ID: 28984737
[TBL] [Abstract][Full Text] [Related]
19. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
Jin E; Yin H; Li X; Zhao M
Retina; 2018 Aug; 38(8):1595-1604. PubMed ID: 28699927
[TBL] [Abstract][Full Text] [Related]
20. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity.
Salman AG; Said AM
Ophthalmic Res; 2015; 53(1):15-20. PubMed ID: 25471087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
